Vimarsana
Biggest News Aggregation in the World

Page 26 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

Lynparza shows promise in preventing cancer recurrence - Vimarsana News

Lynparza shows promise in preventing cancer recurrence

Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting - News - PharmaTimes

Tagrisso approved in EU for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer - Vimarsana News

Tagrisso approved in EU for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II...

AstraZeneca PLC receives EU approval for lung cancer drug Tagrisso - Vimarsana News

AstraZeneca PLC receives EU approval for lung cancer drug Tagrisso

Tagrisso reduced the risk of disease recurrence or death by 80% in the overall trial population of patients

EU clears Tagrisso for early-stage EGFR-mutated lung cancer - Vimarsana News

EU clears Tagrisso for early-stage EGFR-mutated lung cancer

EU clears Tagrisso for early-stage EGFR-mutated lung cancer 28th May 2021 The European Commission (EC) has approved AstraZeneca’s (AZ) Tagrisso for the adjuvant treatment of early-stage, epidermal growth factor receptor mutated (EGFR) non-small cell lung cancer (NSCLC) following surgery. The EC approval is based on results from the Phase III ADAURA trial, within which adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% in patients with Stage II and IIIA disease, and by 80% in the overall trial population in patients with Stage IB-IIIA disease. In addition...

AZ's Tagrisso approved for EGFR-positive NSCLC in the EU - Vimarsana News

AZ's Tagrisso approved for EGFR-positive NSCLC in the EU

AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU European Commission approved Tagrisso in this setting based on positive results from the ADAURA phase 3 study AstraZeneca’s (AZ) third-generation EGFR tyrosine kinase inhibitor (TKI) Tagrisso has been approved to treat early-stage EGFR mutated non-small cell lung cancer (NSCLC) in the EU. The European Commission has approved Tagrisso (osimertinib) in this setting based on positive results from the ADAURA phase 3 study. In this trial, adjuvant Tagrisso treatment was found to reduce the risk of disease recurrence or death by 80% in t...

Source: pmlive.com